Key result
The decorin mimic DS-SILY reduced in vitro smooth muscle cell migration by 95% and in vivo neointimal hyperplasia by 60% following balloon angioplasty in an Ossabaw swine model.
Why the study?
Does the decorin mimic DS-SILY inhibit vascular smooth muscle proliferation, migration, and neointimal hyperplasia in preclinical models?
Does the decorin mimic DS-SILY inhibit vascular smooth muscle proliferation, migration, and neointimal hyperplasia in preclinical models?
Answers are grounded in this paper and cite their sources.
The decorin mimic DS-SILY shows promise as a novel anti-restenotic therapy by synergistically inhibiting SMC proliferation, migration, and platelet activation.
Over the past 10 years, the number of percutaneous coronary intervention procedures performed in the United States increased by 33%; however, restenosis, which inhibits complete functional recovery of the vessel wall, complicates this procedure. A wide range of anti-restenotic therapeutics have been developed, although many elicit non-specific effects that compromise vessel healing. Drawing inspiration from biologically-relevant molecules, our lab developed a mimic of the natural proteoglycan decorin, termed DS-SILY, which can mask exposed collagen and thereby effectively decrease platelet activation, thus contributing to suppression of vascular intimal hyperplasia. Here, we characterize the effects of DS-SILY on both proliferative and quiescent human SMCs to evaluate the potential impact of DS-SILY-SMC interaction on restenosis, and further characterize in vivo platelet interactions. DS-SILY decreased proliferative SMC proliferation and pro-inflammatory cytokine secretion in vitro in a concentration dependent manner as compared to untreated controls. The addition of DS-SILY to in vitro SMC cultures decreased SMC migration and protein synthesis by 95% and 37%, respectively. Furthermore, DS-SILY decreased platelet activation, as well as reduced neointimal hyperplasia by 60%, in vivo using Ossabaw swine. These results indicate that DS-SILY demonstrates multiple biological activities that may all synergistically contribute to an improved treatment paradigm for balloon angioplasty.
No takes yet. Share an insight, caveat, or question.
Scott et al. (2013) studied Restenosis and Neointimal Hyperplasia. DS-SILY20 (Decorin mimic) vs. Saline or untreated controls was evaluated on Neointimal hyperplasia (in vivo) (60% reduction, p=<0.05). The decorin mimic DS-SILY reduced in vitro smooth muscle cell migration by 95% and in vivo neointimal hyperplasia by 60% following balloon angioplasty in an Ossabaw swine model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: